This grant is for supporting product-driven preclinical studies of promising novel lead agents or medical devices that could significantly improve prostate cancer clinical care. The Department of Defense seeks proposals that aim to transition innovative laboratory discoveries into clinical applications. For lead agents, applicants must demonstrate a validated target, access to agents for optimization, and their mechanism of action, supported by preliminary data on target availability in human tissues and efficacy in model systems. For medical devices, preliminary data must prove reliability, reproducibility, and effectiveness. This award covers research spanning from preclinical studies to cGMP production, fostering the development of revolutionary solutions for prostate cancer.
Opportunity ID: 156514
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-12-PCRP-LCTA |
| Funding Opportunity Title: | DoD Prostate Cancer Laboratory-Clinical Transition Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 20, 2012 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Aug 23, 2012 |
| Current Closing Date for Applications: | Aug 23, 2012 |
| Archive Date: | Sep 22, 2012 |
| Estimated Total Program Funding: | $4,800,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | Supports product-driven preclinical studies of promising novel lead agents or medical devices that have the potential to revolutionize prostate cancer clinical care. For lead agents, PIs are expected to demonstrate within the application (1) a validated target, (2) access to either one lead agent or a limited number of lead agents for optimization, and (3) the agents mechanism of action. For lead agents, preliminary data should demonstrate validated target availability and distribution in relevant human tissues and substantive information from model systems that supports potential efficacy of the lead agent(s) in humans. For medical devices preliminary data should demonstrate reliability, reproducibility and effectiveness for the medical device. Supports research that ranges from preclinical study through cGMP production. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk: 301-682-5507
Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 156514 Full Announcement-1 -> fy12 cdmrp gai final 12mar2012.pdf
Folder 156514 Full Announcement-1 -> pcrp_fy12_lcta_ pa_gg.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk: 301-682-5507 Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00108890 | Mar 20, 2012 | Aug 23, 2012 | View |
Package 1
Mandatory forms
156514 RR_SF424_1_2-1.2.pdf
156514 PerformanceSite_1_4-1.4.pdf
156514 RR_Budget-1.1.pdf
156514 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
156514 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
